ribosomal protein S24 pseudogene 21Genealiases: []
Q-omics provides the consensus-scored RPS24P21 profile across patient tissues and cancer cell-line models. RPS24P21 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RPS24P21 is differentially expressed in 4, with the highest sampling consensus in KIRP. Additionally, RPS24P21 RNA expression shows 4,282 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, KIRP, and STAD as cancer lineages where RPS24P21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS24P21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS24P21 survival associations across molecular data types. RPS24P21 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS24P21 RNA expression–survival associations across cancer types. High RPS24P21 expression shows unfavorable associations in OV, ACC, PCPG and UCS, but favorable associations in BLCA and UVM. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .024). Together, the overview and detailed table identify BLCA as the clearest survival context for RPS24P21 RNA expression.
This table summarizes RPS24P21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RPS24P21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS24P21 shows lower tumor expression in KIRP, KIRC and KICH and higher tumor expression in COAD. The KIRP box plot shows higher RPS24P21 RNA expression in normal versus tumor tissue (log2 FC = −0.174, t-test p = .003).
This table shows molecular features associated with RPS24P21 in patient tissues and cancer cell lines. In patient samples, RPS24P21 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
